ARS Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $18 to $22.
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $18 to $22.
August 13, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and increased the price target from $18 to $22, leading to a rise in the stock price.
The upgrade from Raymond James to Strong Buy and the increased price target are strong positive signals for investors, likely leading to increased buying activity and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100